| Alena G Goldman, MD | |
|
77 Herrick St, Beverly, MA 01915-2734 | |
| (978) 927-4110 | |
| Not Available |
| Full Name | Alena G Goldman |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 21 Years |
| Location | 77 Herrick St, Beverly, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528388303 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 244908 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth's Medical Center | Brighton, MA | Hospital |
| Carney Hospital | Boston, MA | Hospital |
| Good Samaritan Medical Center | Brockton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
"Devastating" and "dismal." That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
› Verified 3 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
"Devastating" and "dismal." That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
› Verified 3 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
"Devastating" and "dismal." That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alena G Goldman, MD 77 Herrick St, Beverly, MA 01915-2734 Ph: (978) 927-4110 | Alena G Goldman, MD 77 Herrick St, Beverly, MA 01915-2734 Ph: (978) 927-4110 |
News Archive
"Devastating" and "dismal." That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.
Less than a decade ago, the Food and Drug Administration approved drugs for treating type 2 diabetes in an entirely new way.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.
› Verified 3 days ago
Ronald Newman, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Lahey At Beverly Hospital, Beverly, MA 01915 Phone: 978-922-3000 | |
Joel W Shelkrot, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Beverly Hospital, Herrick Street, Beverly, MA 01915 Phone: 978-922-3000 | |
Dr. Ariadne Stephanie Scott Iriarte, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 | |
Pierre Abou-ezzi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Cummings Center, Suite 126q, Beverly, MA 01915 Phone: 978-524-8181 Fax: 978-524-9868 | |
Thuy Le, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 Fax: 978-524-6088 | |
Dr. David Goldberg, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Lahey Cardiology, Beverly, 75 Herrick Street Suite 206, Beverly, MA 01915 Phone: 978-927-8400 Fax: 978-922-1452 | |
Dorina Omari, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 100 Cummings Ctr, Suite 166 D, Beverly, MA 01915 Phone: 978-712-3360 Fax: 978-712-3392 |